The Lancet Infectious Diseases, January 2018 Earlier this year, the use of procalcitonin in guiding antibiotic therapy for patients with acute respiratory infections was approved by the US Food and Drug Administration. To assess the safety of procalcitonin-guided treatments with ARI in different clinical settings, Prof. Philipp Schuetz, et al. conducted a meta-analysis of 26 randomized controlled trials.
"Widespread implementation of procalcitonin protocols in patients with acute respiratory infections thus has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance."
Read the full article here: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30592-3/fulltext?elsca1=etoc